1. Home
  2. SGP vs GSBD Comparison

SGP vs GSBD Comparison

Compare SGP & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$24.39

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

GSBD

Goldman Sachs BDC Inc.

HOLD

Current Price

$9.40

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGP
GSBD
Founded
2019
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
932.9M
1.0B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SGP
GSBD
Price
$24.39
$9.40
Analyst Decision
Strong Buy
Sell
Analyst Count
5
2
Target Price
$45.00
$9.00
AVG Volume (30 Days)
59.1K
1.3M
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
13.49%
EPS Growth
N/A
87.27
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$9.68
Revenue Growth
N/A
N/A
52 Week Low
$20.15
$8.66
52 Week High
$30.56
$12.03

Technical Indicators

Market Signals
Indicator
SGP
GSBD
Relative Strength Index (RSI) 47.66 43.46
Support Level $20.95 $8.89
Resistance Level $26.55 $9.53
Average True Range (ATR) 1.42 0.22
MACD 0.19 -0.02
Stochastic Oscillator 52.86 14.07

Price Performance

Historical Comparison
SGP
GSBD

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Share on Social Networks: